Wall Street analysts expect Novartis (NVS) to post quarterly earnings of $2.20 per share in its upcoming report, which indicates a year-over-year decline of 9.1%. Revenues are expected to be $13.96 billion, down 0.6% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Novartis metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Oncology- Tafinlar + Mekinist- Total' to come in at $533.22 million. The estimate indicates a change of -6.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Net sales to third parties' at $13.96 billion. The estimate suggests a change of -0.6% year over year.
Based on the collective assessment of analysts, 'Revenues- Oncology- Kisqali- Total' should arrive at $1.72 billion. The estimate indicates a year-over-year change of +46%.
According to the collective judgment of analysts, 'Revenues- Immunology- Cosentyx- Total' should come in at $1.72 billion. The estimate points to a change of +5.4% from the year-ago quarter.
The consensus estimate for 'Revenues- Oncology- Tasigna- US' stands at $24.84 million. The estimate indicates a year-over-year change of -84.7%.
The consensus among analysts is that 'Net sales- Oncology- Scemblix- ROW' will reach $165.13 million. The estimate points to a change of +54.3% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Oncology- Promacta/Revolade- US' will reach $23.52 million. The estimate indicates a change of -89.6% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenues- Immunology- Cosentyx- US' will likely reach $952.68 million. The estimate indicates a change of +3.4% from the prior-year quarter.
Analysts forecast 'Revenues- Cardiovascular- Entresto- US' to reach $66.99 million. The estimate points to a change of -94.5% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Oncology- Tasigna- ROW' reaching $116.53 million. The estimate suggests a change of -29.4% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Oncology- Tafinlar + Mekinist- ROW' of $347.83 million. The estimate indicates a year-over-year change of +6.4%.
Analysts predict that the 'Revenues- Oncology- Promacta/Revolade- ROW' will reach $154.24 million. The estimate suggests a change of -43.9% year over year.
View all Key Company Metrics for Novartis here>>>Over the past month, shares of Novartis have returned -0.1% versus the Zacks S&P 500 composite's +0.5% change. Currently, NVS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).